Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Pharmaceutical Corporation and Cytovance Biologics Sign Deal for the Process Development and cGMP Manufacture of Selexys Pharmaceutical Corporation’s Product HPL1 Monoclonal Antibody (Mab)

By Pharmaceutical Processing | January 26, 2009

Cytovance(R) Biologics LLC, a biopharmaceutical contract manufacturing company specializing in mammalian cell culture, today announced the signing of a full service process development and manufacturing collaboration with Selexys Pharmaceutical Corporation. “Selexys is pleased to announce the selection of Cytovance Biologics as our contract manufacturer for our lead drug candidate for Crohn’s disease. Cytovance brings substantial expertise in biologics manufacturing that will serve to advance our lead drug candidate into clinical development,” said Scott Rollins, President and CEO Selexys Pharmaceutical Corporation. “We are very excited to join in this collaboration with Selexys on the development of their drug candidate. It is great to be able to continue to combine expertise from two Oklahoma City-based companies working so close together,” said Darren Head, President and CEO Cytovance Biologics. The Selexys Pharmaceutical Corporation project is to be executed in Cytovance’s multi-product Process Development and cGMP production facility in Oklahoma City over the next fifteen months. The project team will be composed of members of both Oklahoma City-based organizations working closely together. The 44,000 sq. ft. facility meets the latest international regulatory standards and is custom-designed for efficient and cost-effective production. Cytovance specializes in the execution of clinical and commercial production of antibody and recombinant protein products derived from cell culture and microbial fermentation at scales up to 500L (w/v) from both fed-batch and perfusion processes and 100L Disposable Bioreactors.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE